Key result
Technological advances enable single-stage implantation of dual centrifugal pumps for biventricular support in end-stage HF.
Why the study?
Survival in patients with end-stage chronic heart failure on medical treatment remains extremely low, stimulating the development of surgical methods of treatment.
This review discusses the evolution and current state of biventricular mechanical circulatory support as an alternative to total artificial heart for end-stage heart failure.
May expand biventricular support options but should not yet alter practice; leaves open prospective outcome trials.
Medical management of end-stage chronic heart failure (HF) has evolved significantly over the past few decades. With a better understanding of the pathophysiology of HF, new pharmacological agents have been synthesized. However, survival in this cohort of patients with medical treatment remains extremely low. This has stimulated the development of surgical methods of treatment. Recent technological advances in the development of mechanical circulatory assist devices have made possible a single-stage implantation of two centrifugal pumps as an alternative to a total artificial heart. Today ventricular assist devices can be implanted to provide both univentricular and biventricular support depending on the severity of hemodynamic disorders, target organ damage, likelihood of recovery and heart transplantation.
No takes yet. Share an insight, caveat, or question.
Zhulkov et al. (2023) conducted a review in end-stage chronic heart failure. Biventricular mechanical circulatory support was evaluated. Recent technological advances in mechanical circulatory assist devices have enabled single-stage implantation of two centrifugal pumps for biventricular support in end-stage chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: